Novo Nordisk-Akero Therapeutics deal gets green light in US
Diabetes and obesity drug manufacturer Novo Nordisk’s $5.2 billion deal for clinical-stage metabolic disease drug manufacturer Akero Therapeutics has received clearance from the US competition authorities. The deal was granted early...To view the full article, register now.
Already a subscriber? Click here to view full article